• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自一项结直肠癌筛查项目中粪便免疫化学检测呈阳性但结肠镜检查结果为阴性的参与者发生的结直肠癌。

Colorectal cancer after negative colonoscopy in fecal immunochemical test-positive participants from a colorectal cancer screening program.

作者信息

Rivero-Sánchez Liseth, Grau Jaume, Augé Josep María, Moreno Lorena, Pozo Angels, Serradesanferm Anna, Díaz Mireia, Carballal Sabela, Sánchez Ariadna, Moreira Leticia, Balaguer Francesc, Pellisé Maria, Castells Antoni

机构信息

Gastroenterology Department, Hospital Clinic of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universitat de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Preventive Medicine and Hospital Epidemiology Department, Hospital Clínic, Barcelona, Spain.

出版信息

Endosc Int Open. 2018 Sep;6(9):E1140-E1148. doi: 10.1055/a-0650-4296. Epub 2018 Sep 11.

DOI:10.1055/a-0650-4296
PMID:30211305
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6133669/
Abstract

Colorectal cancer (CRC) risk after a positive fecal immunochemical test (FIT) and negative colonoscopy is unknown. We aimed to ascertain the cumulative incidence of post-colonoscopy colorectal cancer (PCCRC) and the manifestation of other lesions that could explain the test positivity in individuals with a negative colonoscopy in a population screening program.  Observational study in participants from the first round of a CRC screening program (2010 - 2012) with positive-FIT (≥ 20 μg/g of feces) and negative colonoscopy (without neoplasia). A 42- to 76-month follow-up was performed searching in the National Health Service database and by a brief structured telephonic interview.  Of 2659 FIT-positive individuals who underwent colonoscopy, 811 (30.5 %) had a negative colonoscopy. Three PCCRC (0.4 %) were detected within 11 - 28 months and accelerated carcinogenesis was ruled out. Among those with normal colonoscopy, 32 (5 %) relevant lesions were detected at follow-up. One-third of them (11/32) were significant neoplasias: a gastric cancer, a small-bowel lymphoma, six advanced colorectal adenomas, and the three PCCRC. The 21 remaining lesions were inflammatory, vascular disorders, or non-advanced colorectal adenomas.  The vast majority (95 %) of individuals did not present any subsequent lesion that could explain the FIT positivity. The very low incidence (0.4 %) and characteristics of PCCRC observed in our cohort reinforce the concept that, although a positive FIT preselects high risk individuals, a high quality colonoscopy is the paramount factor in preventing PCCRC. Improving quality standards of colonoscopy are required to strengthen the current CRC screening strategies.

摘要

粪便免疫化学试验(FIT)结果呈阳性而结肠镜检查结果为阴性后的结直肠癌(CRC)风险尚不清楚。我们旨在确定结肠镜检查后结直肠癌(PCCRC)的累积发病率,以及在人群筛查项目中结肠镜检查结果为阴性的个体中,其他可解释检测阳性的病变表现。

对第一轮CRC筛查项目(2010 - 2012年)中FIT阳性(≥20μg/g粪便)且结肠镜检查阴性(无肿瘤形成)的参与者进行观察性研究。通过在国家卫生服务数据库中检索并进行简短的结构化电话访谈,进行了42至76个月的随访。

在接受结肠镜检查的2659名FIT阳性个体中,811名(30.5%)结肠镜检查结果为阴性。在11至28个月内检测到3例PCCRC(0.4%),并排除了加速癌变的可能。在结肠镜检查正常的个体中,随访期间检测到32例(5%)相关病变。其中三分之一(11/32)为显著肿瘤:1例胃癌、1例小肠淋巴瘤、6例晚期结直肠腺瘤和3例PCCRC。其余21例病变为炎症、血管疾病或非晚期结直肠腺瘤。

绝大多数(95%)个体未出现任何可解释FIT阳性的后续病变。我们队列中观察到的PCCRC发病率极低(0.4%)及其特征强化了这样一个概念,即尽管FIT阳性预先选择了高风险个体,但高质量的结肠镜检查是预防PCCRC的首要因素。需要提高结肠镜检查的质量标准以加强当前的CRC筛查策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99e1/6133669/2d1b97c5c3d1/10-1055-a-0650-4296-i1171ei2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99e1/6133669/17ed645637d2/10-1055-a-0650-4296-i1171ei1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99e1/6133669/2d1b97c5c3d1/10-1055-a-0650-4296-i1171ei2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99e1/6133669/17ed645637d2/10-1055-a-0650-4296-i1171ei1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99e1/6133669/2d1b97c5c3d1/10-1055-a-0650-4296-i1171ei2.jpg

相似文献

1
Colorectal cancer after negative colonoscopy in fecal immunochemical test-positive participants from a colorectal cancer screening program.来自一项结直肠癌筛查项目中粪便免疫化学检测呈阳性但结肠镜检查结果为阴性的参与者发生的结直肠癌。
Endosc Int Open. 2018 Sep;6(9):E1140-E1148. doi: 10.1055/a-0650-4296. Epub 2018 Sep 11.
2
Adenoma Detection Rate and Colorectal Cancer Risk in Fecal Immunochemical Test Screening Programs : An Observational Cohort Study.粪便免疫化学检测筛查项目中的腺瘤检出率与结直肠癌风险:一项观察性队列研究
Ann Intern Med. 2023 Mar;176(3):303-310. doi: 10.7326/M22-1008. Epub 2023 Feb 21.
3
Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.更高的粪便免疫化学检测截断值对后续轮次结直肠筛查项目中检出的病理结果的影响。
Gastrointest Endosc. 2019 Mar;89(3):518-522. doi: 10.1016/j.gie.2018.08.015. Epub 2018 Aug 22.
4
Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.粪便免疫化学试验阳性者参加结直肠癌筛查项目的口腔和上消化道癌症风险。
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1237-1243.e2. doi: 10.1016/j.cgh.2018.01.037. Epub 2018 Feb 7.
5
Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.增加结直肠癌筛查计划的筛查年龄和粪便血红蛋白截断浓度的效果。
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1771-1777. doi: 10.1016/j.cgh.2016.08.016. Epub 2016 Aug 24.
6
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.多次粪便免疫化学检测受试者的间期结直肠癌发病率。
Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5.
7
Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.粪便免疫化学检测与结肠镜检查在家族性结直肠癌筛查中的等效性。
Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.
8
Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.免疫化学粪便潜血试验对近端和远端进展期肿瘤同样敏感。
Am J Gastroenterol. 2012 Oct;107(10):1570-8. doi: 10.1038/ajg.2012.249. Epub 2012 Jul 31.
9
Post-colonoscopy colorectal cancer: Characteristics and predictive factors.结肠镜检查后的结直肠癌:特征和预测因素。
Med Clin (Barc). 2018 Jan 12;150(1):1-7. doi: 10.1016/j.medcli.2017.04.015. Epub 2017 Jun 10.
10
Performance of the Fecal Immunochemical Test in Patients With a Family History of Colorectal Cancer.粪便免疫化学检测在有结直肠癌家族史患者中的表现
J Can Assoc Gastroenterol. 2019 Oct 4;3(6):288-292. doi: 10.1093/jcag/gwz027. eCollection 2020 Dec.

引用本文的文献

1
Optimizing Urgent Suspected Colon Cancer Referrals and Reducing Colonoscopy Wait Times in Wales.优化威尔士紧急疑似结肠癌转诊并缩短结肠镜检查等待时间
Cureus. 2024 Dec 29;16(12):e76597. doi: 10.7759/cureus.76597. eCollection 2024 Dec.
2
Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test.基于粪便的结直肠癌筛查试验呈阳性后结肠镜检查结果为阴性的患者中的间期进展性腺瘤和肿瘤形成
Dig Dis Sci. 2025 Jan;70(1):350-359. doi: 10.1007/s10620-024-08748-4. Epub 2024 Nov 24.
3
Effect of aspirin, warfarin, and proton-pump inhibitors on performance of fecal immunochemical test in colorectal cancer screening: a systematic review and meta-analysis.

本文引用的文献

1
Long-term risk of colorectal cancer after negative colonoscopy in a Danish gFOBT screening cohort.丹麦粪便潜血试验筛查队列中结肠镜检查结果为阴性后的结直肠癌长期风险
Int J Cancer. 2017 Aug 1;141(3):503-511. doi: 10.1002/ijc.30756. Epub 2017 May 15.
2
Increased Rate of Adenoma Detection Associates With Reduced Risk of Colorectal Cancer and Death.腺瘤检出率增高与结直肠癌发病风险和死亡风险降低相关。
Gastroenterology. 2017 Jul;153(1):98-105. doi: 10.1053/j.gastro.2017.04.006. Epub 2017 Apr 17.
3
Is gastroscopy for fecal immunochemical test positive patients worthwhile?
阿司匹林、华法林和质子泵抑制剂对结直肠癌筛查中粪便免疫化学试验性能的影响:系统评价和荟萃分析。
Clin Exp Med. 2023 Dec;23(8):4355-4368. doi: 10.1007/s10238-023-01196-w. Epub 2023 Oct 7.
4
Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.基于粪便免疫化学试验的筛查方案中,阴性结肠镜检查后的结肠镜检查间期结直肠癌。
Endoscopy. 2023 Dec;55(12):1061-1069. doi: 10.1055/a-2136-6564. Epub 2023 Oct 4.
5
To scope or not - the challenges of managing patients with positive fecal occult blood test after recent colonoscopy.是否进一步检查——近期结肠镜检查后粪便潜血试验阳性患者的管理挑战
World J Gastrointest Oncol. 2022 Sep 15;14(9):1798-1807. doi: 10.4251/wjgo.v14.i9.1798.
6
Using fecal immunochemical tubes for the analysis of the gut microbiome has the potential to improve colorectal cancer screening.使用粪便免疫化学管进行肠道微生物组分析有可能改善结直肠癌筛查。
Sci Rep. 2021 Oct 1;11(1):19603. doi: 10.1038/s41598-021-99046-w.
7
A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test.阳性粪便潜血试验后阴性结肠镜检查的困境:真阳性还是假阴性?
Dig Dis Sci. 2022 May;67(5):1843-1849. doi: 10.1007/s10620-021-06986-4. Epub 2021 May 3.
8
Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers.结直肠癌筛查的未来前景:间隔期癌症的特征分析
Cancers (Basel). 2021 Mar 16;13(6):1328. doi: 10.3390/cancers13061328.
9
Colon Cancer: A Clinician's Perspective in 2019.结肠癌:2019年临床医生的视角
Gastroenterology Res. 2020 Feb;13(1):1-10. doi: 10.14740/gr1239. Epub 2020 Feb 1.
10
Single dose aspirin affects fecal immunohistochemical test sensitivity in detecting advanced colorectal neoplasms: Truth or expectation?单剂量阿司匹林对粪便免疫组织化学检测晚期结直肠肿瘤的敏感性有影响:事实还是期望?
Turk J Gastroenterol. 2020 Jan;31(1):80-82. doi: 10.5152/tjg.2020.090120.
粪便免疫化学检测呈阳性的患者进行胃镜检查是否值得?
Int J Colorectal Dis. 2017 Jan;32(1):95-98. doi: 10.1007/s00384-016-2666-7. Epub 2016 Sep 30.
4
Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening.在使用粪便免疫化学检测进行结直肠癌筛查时出现假阳性结果的处方药。
Dig Liver Dis. 2016 Oct;48(10):1249-54. doi: 10.1016/j.dld.2016.06.011. Epub 2016 Jun 21.
5
Proton Pump Inhibitors Inhibit Pancreatic Secretion: Role of Gastric and Non-Gastric H+/K+-ATPases.质子泵抑制剂抑制胰腺分泌:胃和非胃H⁺/K⁺-ATP酶的作用
PLoS One. 2015 May 18;10(5):e0126432. doi: 10.1371/journal.pone.0126432. eCollection 2015.
6
[Bowel preparation for colonoscopy. Any significant progress on the horizon?].[结肠镜检查的肠道准备。近期有任何重大进展吗?]
Gastroenterol Hepatol. 2015 Apr;38(4):287-300. doi: 10.1016/j.gastrohep.2014.10.008. Epub 2014 Dec 10.
7
Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably depending on the method used to calculate them: a retrospective observational population-based study of PCCRC in the English National Health Service.结肠镜检查后结直肠癌(PCCRC)的发生率因计算方法的不同而有很大差异:一项基于英国国民医疗服务体系中PCCRC的回顾性观察性人群研究。
Gut. 2015 Aug;64(8):1248-56. doi: 10.1136/gutjnl-2014-308362. Epub 2014 Nov 21.
8
Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature.结直肠间隔癌的定义和分类:标准化命名建议。
Gut. 2015 Aug;64(8):1257-67. doi: 10.1136/gutjnl-2014-307992. Epub 2014 Sep 5.
9
Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.粪便免疫化学试验为基础的筛查方案对结直肠癌死亡率的影响。
Gut. 2015 May;64(5):784-90. doi: 10.1136/gutjnl-2014-307508. Epub 2014 Sep 1.
10
Prevalence, risk factors, and outcomes of interval colorectal cancers: a systematic review and meta-analysis.间隔期结直肠癌的流行率、风险因素和结局:系统评价和荟萃分析。
Am J Gastroenterol. 2014 Sep;109(9):1375-89. doi: 10.1038/ajg.2014.171. Epub 2014 Jun 24.